Roman Kasianov

A new partnership between Corti and BigHand will bring a specialized AI tool to 40,000 healthcare workers across 76 NHS trusts. The tool is designed to reduce administrative work by up to 80%, giving staff more time to focus on patient care.

Corti, founded in 2016, has processed over 100 million patient interactions, refining its AI to suit healthcare environments. BigHand specializes in workflow and documentation tools for healthcare providers, aiming to reduce admin tasks and improve efficiency.

New research commissioned by ArisGlobal, a provider of life sciences technology solutions, reveals that surging regulatory workloads are forcing life sciences companies to prioritize advanced AI adoption in regulatory affairs (RA). The survey, conducted by Censuswide in September 2024, gathered insights from 100 senior regulatory professionals in U.S. pharma and biopharma companies, emphasizing the need for next-generation technology to maintain regulatory compliance and commercial viability.

Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year collaboration aimed at improving clinical trial outcomes for oncology and immunology therapies.

Enveda, a biotechnology company transforming nature’s chemistry into medicines using AI, has announced the FDA clearance of an investigational new drug (IND) application for ENV-294. This first-in-class small molecule, designed to treat atopic dermatitis (eczema) and other inflammatory conditions, has now entered Phase 1 clinical trials, with the first patient dosed in late October.

Genesis Therapeutics has announced a collaboration with NVIDIA to advance its AI platform, GEMS (Genesis Exploration of Molecular Space). The partnership is bolstered by an additional equity investment from NVentures, NVIDIA’s venture capital arm, following its participation in Genesis’ $200 million Series B financing in August 2023.

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has released OpenPhenom-S/16, a new publicly accessible foundation model, on Google Cloud’s Vertex AI Model Garden. This development marks a meaningful step forward in how life sciences researchers leverage microscopy data for drug discovery and cellular analysis.

Schrödinger, Inc. (Nasdaq: SDGR) has entered a collaboration and licensing agreement with Novartis to advance drug discovery efforts on multiple targets. This collaboration involves a $150 million upfront payment from Novartis to Schrödinger, with eligibility for up to $2.3 billion in research, regulatory, and commercial milestone payments, as well as tiered royalties on net sales of resulting products.

Recursion researchers have introduced MolE, a new model aimed at improving predictions of chemical and biological properties of molecules by leveraging molecular graphs and a unique pretraining approach. MolE builds on a foundation model concept, utilizing a large volume of unlabeled data to learn molecular patterns and a smaller labeled dataset to refine its predictions.

DeepMind released AlphaFold3’s code, available on GitHub, marking a new stage in AI-based protein structure prediction. AlphaFold3 expands the tool's predictive abilities, now modeling proteins in complex with other biomolecules, including drug targets and DNA, which can significantly advance studies in biopharmaceuticals and structural biology.

Tempus AI has announced its acquisition of Ambry Genetics, from KONICA MINOLTA, INC. for $600 million, comprising $375 million in cash and $225 million in shares. This strategic acquisition expands Tempus’ capabilities in hereditary cancer screening and genetic testing, adding to its precision medicine offerings. Ambry Genetics, originally founded in 1999 by Charlie Dunlop in San Diego, was sold to Konica Minolta in 2017 for $1 billion.